Intravitreal Aflibercept 8mg Injection in patients with neovascular age-related macular degeneration: 60+96 week results from the Phase 3 Pulsar trial

被引：0
|
作者：
Chang, Andrew [1 ]
机构：
[1] Sydney Eye Hosp, Dept Ophthalmol, Sydney, Australia
来源：
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY | 2023年 / 51卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：933 / 933
页数：1
相关论文
共 50 条
  • [1] Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-week results from the Phase 3 PULSAR trial
    Spitzer, Martin Stephan
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [2] Tolerability and safety of intravitreal aflibercept 8 mg in the Phase 3 PULSAR trial of patients with neovascular age-related macular degeneration
    Korobelnik, Jean-Francois
    Schmidt-Ott, Ursula Maria
    Schulze, Andrea
    Zhang, Xin
    Leal, Sergio
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [3] Evaluation of 8 mg Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Results from the Phase 2 CANDELA Study
    Brown, David M.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [4] Aflibercept for Intravitreal Injection In Neovascular Age-Related Macular Degeneration
    Frampton, James E.
    [J]. DRUGS & AGING, 2012, 29 (10) : 839 - 846
  • [5] Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial
    Lanzetta, Paolo
    Korobelnik, Jean-Francois
    Heier, Jeffrey S.
    Leal, Sergio
    Holz, Frank G.
    Clark, W. Lloyd
    Eichenbaum, David
    Iida, Tomohiro
    Xiaodong, Sun
    Berliner, Alyson J.
    Schulze, Andrea
    Schmelter, Thomas
    Schmidt-Ott, Ursula
    Zhang, Xin
    Vitti, Robert
    Chu, Karen W.
    Reed, Kimberly
    Rao, Rohini
    Bhore, Rafia
    Cheng, Yenchieh
    Sun, Wei
    Hirshberg, Boaz
    Yancopoulos, George
    Wong, Tien Y.
    [J]. LANCET, 2024, 403 (10432): : 1141 - 1152
  • [6] Subgroup analyses from the Phase 3 PULSAR trial of aflibercept 8 mg in patients with treatment-naive neovascular age-related macular degeneration
    Sivaprasad, Sobha
    Leal, Sergio
    Machewitz, Tobias
    Zhang, Xin
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [7] Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration
    Ohr, Matthew
    Kaiser, Peter K.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (04) : 585 - 591
  • [8] Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration
    Matsumoto, Hidetaka
    Hoshino, Junki
    Numaga, Saki
    Mimura, Kaori
    Asatori, Yosuke
    Akiyama, Hideo
    [J]. JAPANESE JOURNAL OF OPHTHALMOLOGY, 2024, 68 (05) : 531 - 537
  • [9] Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration Ninety-Six-Week Results of the VIEW Studies
    Schmidt-Erfurth, Ursula
    Kaiser, Peter K.
    Korobelnik, Jean-Francois
    Brown, David M.
    Chong, Victor
    Quan Dong Nguyen
    Ho, Allen C.
    Ogura, Yuichiro
    Simader, Christian
    Jaffe, Glenn J.
    Slakter, Jason S.
    Yancopoulos, George D.
    Stahl, Neil
    Vitti, Robert
    Berliner, Alyson J.
    Soo, Yuhwen
    Anderesi, Majid
    Sowade, Olaf
    Zeitz, Oliver
    Norenberg, Christiane
    Sandbrink, Rupert
    Heier, Jeffrey S.
    [J]. OPHTHALMOLOGY, 2014, 121 (01) : 193 - 201
  • [10] INTRAVITREAL ZIV-AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION 52-Week Results
    de Oliveira Dias, Joao R.
    De Andrade, Gabriel Costa
    Kniggendorf, Vinicius F.
    Novais, Eduardo A.
    Takahashi, Vitor K. L.
    Maia, Andre
    Meyer, Carsten
    Watanabe, Sung E. S.
    Farah, Michel E.
    Rodrigues, Eduardo B.
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2019, 39 (04): : 648 - 655
12345